Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Bausch & Lomb Incorporated
483
•Bausch & Lomb Incorporated•March 20, 2026

Bausch & Lomb Incorporated – FDA 483, Mar 20, 2026

Record Details

From March 12 to March 20, 2026, the FDA inspected the Bausch and Lomb Incorporated facility in Tampa, Florida, a manufacturer of sterile drug products. The inspection resulted in a Form 483 identifying several critical failures in quality control and manufacturing safety. Primary violations included the inadequate investigation of serious customer complaints involving foreign materials such as metal shards, glass-like particles, and black residue. Notably, the firm failed to file a required Field Alert Report after discovering Pseudomonas aeruginosa in a product container. Further observations highlighted significant lapses in sterility protocols. Staff were observed engaging in improper aseptic behaviors, such as moving too quickly in cleanrooms and mishandling sterile gloves. The facility also recorded over 250 instances of microbial and mold contamination in supposedly sterile areas but failed to perform thorough investigations or identify specific bacterial strains. Additionally, the inspection revealed deficiencies in material handling, including missing documentation for quarantined shipments and inventory storage errors that could lead to product mix-ups. These findings were issued under Section 704 of the Food, Drug, and Cosmetic Act. While the report is not a final determination of non-compliance, Bausch and Lomb is expected to respond with a comprehensive corrective action plan. This plan must address the root causes of contamination and improve documentation standards to ensure the safety and integrity of their sterile pharmaceutical products.

Company
Bausch & Lomb Incorporated
Inspection date
March 20, 2026
Product type
drugs
Office
Florida District Office
People
  • Damaris V. Hernandez
  • Santos E. Camara
  • Mickell Smith
View Company Profile

ID · e099d42a-12de-44a3-ae24-8313e373dec5

Violation Codes2
FD&C Act 70421 U.S.C. 374

Full citation text and observation details available on the Dashboard.

Other documents for Bausch & Lomb Incorporated
  • 483 - 2017-05-26May 26, 2017
  • EIR - 2017-05-26May 26, 2017
  • 483 - 2016-02-25February 25, 2016
  • EIR - 2016-02-25February 25, 2016
  • WARNING_LETTER - 2012-10-02October 2, 2012

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Bausch & Lomb Incorporated
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.